We are live on ! Find out more
COGT icon

Cogent Biosciences

305 hedge funds and large institutions have $7.17B invested in Cogent Biosciences in 2026 Q1 according to their latest regulatory filings, with 80 funds opening new positions, 116 increasing their positions, 82 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

122% more first-time investments, than exits

New positions opened: 80 | Existing positions closed: 36

41% more repeat investments, than reductions

Existing positions increased: 116 | Existing positions reduced: 82

34% more call options, than puts

Call options by funds: $36.3M | Put options by funds: $27M

16% more capital invested

Capital invested by funds: $6.18B → $7.17B (+$986M)

14% more funds holding

Funds holding: 267305 (+38)

7.47% less ownership

Funds ownership: 122.27%114.8% (-7.5%)

12% less funds holding in top 10

Funds holding in top 10: 2522 (-3)

Holders
305
Holders Change
+38
Holders Change %
+14.23%
% of All Funds
3.75%
Holding in Top 10
22
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-12%
% of All Funds
0.27%
New
80
Increased
116
Reduced
82
Closed
36
Calls
$36.3M
Puts
$27M
Net Calls
+$9.21M
Net Calls Change
+$3.98M
Name Holding Trade Value Shares
Change
Change in
Stake
SEI Investments
101
SEI Investments
Pennsylvania
$7.6M +$668K +18,096 +10%
HS
102
HighVista Strategies
Massachusetts
$7.58M -$5.16M -139,616 -41%
Man Group
103
Man Group
United Kingdom
$7.5M -$3.59M -97,281 -33%
AQR Capital Management
104
AQR Capital Management
Connecticut
$7.31M +$2.51M +67,996 +56%
Prudential Financial
105
Prudential Financial
New Jersey
$6.86M +$2.14M +57,990 +48%
TE
106
Tema ETFs
New York
$6.8M +$2.6M +70,338 +66%
RhumbLine Advisers
107
RhumbLine Advisers
Massachusetts
$6.75M -$181K -4,900 -3%
Fisher Asset Management
108
Fisher Asset Management
Washington
$6.44M +$4.41M +119,498 +249%
UBS AM
109
UBS AM
Illinois
$6.37M +$50.6K +1,370 +0.8%
Swiss National Bank
110
Swiss National Bank
Switzerland
$6.37M
SAM
111
SEB Asset Management
$6.33M +$6.07M +164,437 New
OCM
112
Osterweis Capital Management
California
$5.8M +$5.57M +150,810 New
SFCM
113
Seven Fleet Capital Management
California
$5.75M -$2.39M -64,700 -30%
AllianceBernstein
114
AllianceBernstein
Tennessee
$5.59M +$66.5K +1,800 +1%
Connor, Clark & Lunn Investment Management (CC&L)
115
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$5.25M -$1.46M -39,439 -22%
NCM
116
NEXTBio Capital Management
California
$5.05M +$1.31M +35,369 +37%
Deutsche Bank
117
Deutsche Bank
Germany
$4.91M +$677K +18,341 +17%
Rafferty Asset Management
118
Rafferty Asset Management
New York
$4.81M +$514K +13,919 +13%
BFM
119
Boothbay Fund Management
New York
$4.7M -$179K -4,847 -4%
EI
120
EAM Investors
California
$4.69M -$457K -12,367 -9%
PA
121
Perceptive Advisors
New York
$4.66M
AG
122
Algert Global
California
$4.47M -$4.13M -111,808 -49%
SSA
123
Schonfeld Strategic Advisors
New York
$4.33M +$4.15M +112,463 New
PIM
124
Platinum Investment Management
Australia
$4.31M -$338K -9,163 -8%
Creative Planning
125
Creative Planning
Kansas
$4.26M +$770K +20,853 +23%

COGT Hedge Fund Activity: Q1 2026 in Review

305 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q1 2026, worth a combined $7.17B — up 16% from $6.18B a quarter earlier.

Buyers outnumbered sellers: 80 funds opened new COGT positions and 36 closed out — a net gain of 44 holders — while 116 added to existing stakes and 82 trimmed.

The largest buyer was BlackRock, adding an estimated $113M. The largest seller was Fairmount Funds Management, cutting an estimated $129M.

  • 305 institutional investors held Cogent Biosciences (COGT) as of Q1 2026, up from 267 in Q4 2025.
  • Funds reported $7.17B of Cogent Biosciences stock for Q1 2026, up 16% quarter-over-quarter.
  • 80 funds opened new Cogent Biosciences positions in Q1 2026 and 36 closed out, a net change of +44 holders.
  • The largest Cogent Biosciences buyer in Q1 2026 was BlackRock, an estimated $113M added.
  • The largest Cogent Biosciences seller in Q1 2026 was Fairmount Funds Management, an estimated $129M sold.

Based on aggregated 13F filings for Q1 2026.